\-\ Texto\\:\\ \ \(0\)\
\-\ ast\\:\\ 52\\ \\(h\\)\\ u\\/l\ \(0\)\
\-\ alt\\:\\ \\ 49\\ \\ \\(30\\-65\\)\\ u\\/l\ \(0\)\
\-\ aphos\\:\\ 236\\ \\(h\\)\\ u\\/l\ \(0\)\
\-\ tbili\\:\\ 0\\.7\\ mg\\/dl\ \(0\)\
\-\ dbili\\:\\ 0\\.1\\ mg\\/dl\ \(0\)\
\-\ contrast\\ enhanced\\ images\\ through\\ the\\ liver\\,\\ obtained\\ during\\ the\\ hepatic\\ arterial\\ phase\\ and\\ viewed\\ with\\ liver\\ windows\\,\\ shows\\ multiple\\ nodular\\ hypodensities\\ throughout\\ the\\ liver\\ parenchyma\\,\\ with\\ surrounding\\ peripheral\\ rim\\ enhancement\\ and\\ associated\\ wedge\\-shaped\\ high\\-attenuation\\ areas\\.\ \(0\)\
\-\ contrast\\ enhanced\\ image\\ through\\ the\\ pancreas\\ shows\\ a\\ hypodense\\ mass\\ in\\ the\\ body\\.\\ note\\ the\\ attenuation\\ difference\\ between\\ the\\ tumor\\ and\\ the\\ avidly\\ enhancing\\ normal\\ pancreas\\.\ \(0\)\
\-\ metastatic\\ pancreatic\\ adenocarcinoma\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ transient\\ hepatic\\ attenuation\\ difference\\ \\(thad\\)\\:\ \(0\)\
\-\ hepatocellular\\ carcinoma\\ is\\ the\\ most\\ common\\ primary\\ hepatic\\ tumor\\ associated\\ with\\ thad\\.\\ \\ in\\ regards\\ to\\ cholangiocarcinoma\\,\\ thad\\ is\\ an\\ important\\ indirect\\ sign\\ of\\ vascular\\ invasion\\.\\ \\ metastatic\\ hypervascular\\ lesions\\ from\\ islet\\ cell\\ tumors\\,\\ carcinoids\\,\\ renal\\ cell\\ carcinoma\\,\\ and\\ breast\\ carcinoma\\ may\\ also\\ have\\ this\\ imaging\\ appearance\\.\\ \\ hemangiomas\\,\\ focal\\ nodular\\ hyperplasia\\,\\ pyogenic\\ abscess\\,\\ and\\ focal\\ eosinophilic\\ necrosis\\ are\\ additional\\ differential\\ considerations\\.\\ \\ finally\\,\\ hepatic\\ hemodynamic\\ alterations\\ caused\\ by\\ liver\\ cirrhosis\\,\\ portal\\ or\\ hepatic\\ vein\\ thrombosis\\,\\ and\\ arterioportal\\ shunts\\ may\\ result\\ in\\ thad\\.\ \(0\)\
\-\ 52\\ yo\\ male\\ with\\ ruq\\ pain\\ and\\ abnormal\\ liver\\ associated\\ enzymes\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thad\\:\\ 0\\.45887400974566767\ \(0\)\
\-\ hepatic\\:\\ 0\\.2856272204286321\ \(0\)\
\-\ liver\\:\\ 0\\.24742761783067732\ \(0\)\
\-\ difference\\:\\ 0\\.16694006747607115\ \(0\)\
\-\ attenuation\\:\\ 0\\.16465964995681487\ \(0\)\
\-\ pancreas\\:\\ 0\\.13484049832509226\ \(0\)\
\-\ 52\\:\\ 0\\.1328724072295093\ \(0\)\
\-\ the\\:\\ 0\\.12882203725353442\ \(0\)\
\-\ carcinoma\\:\\ 0\\.12872435629753748\ \(0\)\
\-\ aphos\\:\\ 0\\.11471850243641692\ \(0\)\
\-\ nodular\\:\\ 0\\.11425088817145283\ \(0\)\
\-\ associated\\:\\ 0\\.11342780935471602\ \(0\)\
\-\ arterioportal\\:\\ 0\\.10961965345547645\ \(0\)\
\-\ enhanced\\:\\ 0\\.10923909651846127\ \(0\)\
\-\ and\\:\\ 0\\.10376086894191887\ \(0\)\
\-\ carcinoids\\:\\ 0\\.10319586344471507\ \(0\)\
\-\ dbili\\:\\ 0\\.10090311354966282\ \(0\)\
\-\ alterations\\:\\ 0\\.09896462113433316\ \(0\)\
\-\ 236\\:\\ 0\\.09447932353890144\ \(0\)\
\-\ differential\\:\\ 0\\.09321873373575548\ \(0\)\
\-\ hypodensities\\:\\ 0\\.0921865736438492\ \(0\)\
\-\ regards\\:\\ 0\\.0921865736438492\ \(0\)\
\-\ indirect\\:\\ 0\\.09118001186999601\ \(0\)\
\-\ viewed\\:\\ 0\\.09024808122851954\ \(0\)\
\-\ islet\\:\\ 0\\.08938047455796096\ \(0\)\
\-\ shunts\\:\\ 0\\.08938047455796096\ \(0\)\
\-\ hemodynamic\\:\\ 0\\.08856888271897607\ \(0\)\
\-\ focal\\:\\ 0\\.08581623753169165\ \(0\)\
\-\ through\\:\\ 0\\.0854032460222615\ \(0\)\
\-\ avidly\\:\\ 0\\.08514923224757905\ \(0\)\
\-\ shows\\:\\ 0\\.08420346603262929\ \(0\)\
\-\ tbili\\:\\ 0\\.08295668454719958\ \(0\)\
\-\ cell\\:\\ 0\\.08207046324084186\ \(0\)\
\-\ enzymes\\:\\ 0\\.08198887568196823\ \(0\)\
\-\ pyogenic\\:\\ 0\\.08153154132270592\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.07985234281316245\ \(0\)\
\-\ metastatic\\:\\ 0\\.07868517195671673\ \(0\)\
\-\ hemangiomas\\:\\ 0\\.0783711847570951\ \(0\)\
\-\ windows\\:\\ 0\\.0776912727484823\ \(0\)\
\-\ finally\\:\\ 0\\.0773646229832419\ \(0\)\
\-\ hypervascular\\:\\ 0\\.0758476887753179\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.07556508567120684\ \(0\)\
\-\ tumor\\:\\ 0\\.07504223178657202\ \(0\)\
\-\ considerations\\:\\ 0\\.07424014464138595\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.07374693205836877\ \(0\)\
\-\ ruq\\:\\ 0\\.0728150014168923\ \(0\)\
\-\ may\\:\\ 0\\.07219775983715786\ \(0\)\
\-\ transient\\:\\ 0\\.07055973384138074\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.06983052616440563\ \(0\)\
\-\ contrast\\:\\ 0\\.06970830557325337\ \(0\)\
\-\ hypodense\\:\\ 0\\.06965464485128148\ \(0\)\
\-\ alt\\:\\ 0\\.06897473284266868\ \(0\)\
\-\ ast\\:\\ 0\\.06881034737904776\ \(0\)\
\-\ portal\\:\\ 0\\.0686480830774283\ \(0\)\
\-\ 49\\:\\ 0\\.0677161524359518\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.06539847625147806\ \(0\)\
\-\ pancreatic\\:\\ 0\\.06503039215255516\ \(0\)\
\-\ invasion\\:\\ 0\\.06398668025154804\ \(0\)\
\-\ phase\\:\\ 0\\.061382508394700476\ \(0\)\
\-\ important\\:\\ 0\\.06076464965895407\ \(0\)\
\-\ arterial\\:\\ 0\\.059074689224153154\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.058630808711146655\ \(0\)\
\-\ thrombosis\\:\\ 0\\.05848626333930218\ \(0\)\
\-\ parenchyma\\:\\ 0\\.05827251356598697\ \(0\)\
\-\ caused\\:\\ 0\\.05751845447407084\ \(0\)\
\-\ rim\\:\\ 0\\.057125444085726416\ \(0\)\
\-\ with\\:\\ 0\\.056185763730437474\ \(0\)\
\-\ additional\\:\\ 0\\.055608509877802415\ \(0\)\
\-\ necrosis\\:\\ 0\\.054832694190674186\ \(0\)\
\-\ note\\:\\ 0\\.05400096574387046\ \(0\)\
\-\ result\\:\\ 0\\.0537027230957216\ \(0\)\
\-\ in\\:\\ 0\\.05353537602937704\ \(0\)\
\-\ throughout\\:\\ 0\\.052756765337457934\ \(0\)\
\-\ tumors\\:\\ 0\\.052756765337457934\ \(0\)\
\-\ breast\\:\\ 0\\.052091249791660556\ \(0\)\
\-\ vein\\:\\ 0\\.05141816291694437\ \(0\)\
\-\ peripheral\\:\\ 0\\.051295873698179645\ \(0\)\
\-\ obtained\\:\\ 0\\.05074040698358688\ \(0\)\
\-\ sign\\:\\ 0\\.0496623943987861\ \(0\)\
\-\ areas\\:\\ 0\\.0487025044940783\ \(0\)\
\-\ surrounding\\:\\ 0\\.04784150076874668\ \(0\)\
\-\ vascular\\:\\ 0\\.04735777540526347\ \(0\)\
\-\ body\\:\\ 0\\.0472103492279565\ \(0\)\
\-\ between\\:\\ 0\\.04660936686787774\ \(0\)\
\-\ abscess\\:\\ 0\\.04606252815286587\ \(0\)\
\-\ image\\:\\ 0\\.045876617349196125\ \(0\)\
\-\ during\\:\\ 0\\.04543624227624776\ \(0\)\
\-\ enhancing\\:\\ 0\\.044937156582407316\ \(0\)\
\-\ yo\\:\\ 0\\.04481541982439255\ \(0\)\
\-\ renal\\:\\ 0\\.044670874452548075\ \(0\)\
\-\ primary\\:\\ 0\\.044108755894956615\ \(0\)\
\-\ appearance\\:\\ 0\\.04324573122805442\ \(0\)\
\-\ abnormal\\:\\ 0\\.043096909267528766\ \(0\)\
\-\ enhancement\\:\\ 0\\.04128892080672414\ \(0\)\
\-\ lesions\\:\\ 0\\.04119772889951941\ \(0\)\
\-\ common\\:\\ 0\\.04068147245889683\ \(0\)\
\-\ is\\:\\ 0\\.03928976183552377\ \(0\)\
\-\ imaging\\:\\ 0\\.037698716906774656\ \(0\)\
\-\ most\\:\\ 0\\.037332617369773606\ \(0\)\
\-\ diagnosis\\:\\ 0\\.03718646844760339\ \(0\)\
\-\ have\\:\\ 0\\.035835136413561605\ \(0\)\
\-\ multiple\\:\\ 0\\.03508672787617588\ \(0\)\
\-\ also\\:\\ 0\\.03374168243136813\ \(0\)\
\-\ images\\:\\ 0\\.03318181440975885\ \(0\)\
\-\ male\\:\\ 0\\.031938797506137255\ \(0\)\
\-\ by\\:\\ 0\\.03046247517744955\ \(0\)\
\-\ normal\\:\\ 0\\.029288567345876877\ \(0\)\
\-\ from\\:\\ 0\\.028489758205129955\ \(0\)\
\-\ an\\:\\ 0\\.02743089338928233\ \(0\)\
\-\ mass\\:\\ 0\\.027400525567483146\ \(0\)\
\-\ are\\:\\ 0\\.027219842733666826\ \(0\)\
\-\ pain\\:\\ 0\\.025669114309476188\ \(0\)\
\-\ or\\:\\ 0\\.024955029112328646\ \(0\)\
\-\ this\\:\\ 0\\.024649141472462926\ \(0\)\
\-\ for\\:\\ 0\\.021742066540980647\ \(0\)\
\-\ to\\:\\ 0\\.017933393468636975\ \(0\)\
\-\ of\\:\\ 0\\.014038053199167948\ \(0\)\
